A groundbreaking development in prostate cancer treatment is set to significantly change patient experiences across England. The NHS will now offer stereotactic ablative radiotherapy (SABR), which reduces the number of treatment sessions from 20 to just five. This advanced technique targets cancer cells more precisely, minimising damage to surrounding healthy tissue and potentially leading to fewer side effects.
This shift is particularly relevant for the 17,500 men diagnosed annually with low or intermediate-risk prostate cancer, as many currently opt for active monitoring instead of immediate treatment. With an estimated 3,500 patients likely to choose this new option, the impact on their quality of life could be substantial, allowing them to return to normal activities much sooner.
The introduction of SABR marks a significant step in cancer care, as it has previously been used for other cancers but is now being made available to prostate cancer patients outside of clinical trials. This could pave the way for further advancements in treatment options, especially for high-risk patients, as ongoing trials explore its broader applicability.
As NHS England prepares to roll out this treatment across all 48 radiotherapy centres, the hope is that it will not only enhance patient outcomes but also alleviate the emotional and physical burden of cancer treatment on patients and their families. The response from patients who have experienced SABR has been overwhelmingly positive, highlighting its potential to transform cancer care in the UK.
Source: BBC News
